Co-administration with CYP3A4 inhibitors

Lumeva · Episodic migraine

MI-2026-0061RoutineClosedWithin SLA

LOLuis OrtegaMSL, Neurology (Iberia)

Received: 12 Aug 2026, 07:35 UTC
Channel: MSL
Requestor type: HCP
Country / region / team: Canada · North America · MI Americas
Category: Drug interaction
Response type: Standard response
Owner: LOLuis Ortega
Due: 17 Aug 2026, 07:35 UTC
Responded: 13 Aug 2026, 15:35 UTC
Quality review: Not required
Related insight: —
Related standard response: SR-LMV-007 · Co-administration with CYP3A4 inhibitors (v3)

Workflow

12-stage inquiry workflow (PRD §16). Advancing records an audit event.

Current stageClosedDemo action — not persisted

Routine: 120 h target · Routine 120 h / Urgent 48 h / Critical 24 h

SLA hours

120

Elapsed

32 h

to response

Remaining

88 h

27%

12 Aug 2026, 07:35 UTC
Received via MSL
HCP · Canada
12 Aug 2026, 07:35 UTC
Triage and assignment
Urgency Routine · assigned to MI Americas
13 Aug 2026, 15:35 UTC
Response sent
Standard response · quality review not required
17 Aug 2026, 07:35 UTC
SLA due (120 h)

Demo — drafts are not persisted

AI suggestion available for non-safety inquiries

Draft response

Timestamp	Action	User	Field	Change	Reason	Source	Event
10 Sept 2026, 15:14 UTC	Create	Mei Tanaka	topics	Draft → In progress	—	UI	AUD-002009

Data lineage: MI inquiry platform (IRMS, INT-05) · received 12 Aug 2026 · hourly sync.